AbbVie has Met phase 3, again
The next-generation telisotuzumab adizutecan joins teliso-V in late-stage development.
BeiGene tries where others failed
The company’s CEACAM5 and PRMT5 projects feature among the latest first-in-human entrants.
The month ahead: October’s upcoming events
Approval decisions loom for Opdivo and Lumakras, and earnings season starts again.
Gritstone has a mountain to climb with Granite
The group is persevering with Granite, but funds might be hard to come by.
KRAS strikes back
First-in-human trial initiations reveal four KRAS assets.
Regor’s selective approach attracts Roche
For $850m up front Roche gets to challenge Pfizer.
